Gene Therapy Clinical Trials
Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
The stereotactic body radiation therapy (SBRT) procedure is an emerging alternative to the standard treatment for early stage non-small cell lung cancer (NSCLC), typically lobectomy with lymphadenectomy. This procedure (lobectomy) does not fulfill the medical need as many patients are poor operative candidates or decline surgery.
This study assesses the feasibility of stereotactic body radiation therapy (SBRT) as a tool to produce therapeutically useful computed tomography (CT) scans, using standard water-soluble iodinated compounds as the contrast agents.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Iohexol
- radiation: Computed Tomography (CT)
- device: Cyberknife
- device: Trilogy
- device: True Beam
- radiation: Stereotactic Body Radiation Therapy (SBRT)
- drug: Iodixanol
Eligibility
INCLUSION CRITERIA
- Either:
- Established primary lung cancer/ cancer metastatic to lung, OR
- Lesion suspicious for malignancy in lung, according to the following criteria:
- Histopathologically confirmed lung cancer or cancer metastatic to lung, OR
- Plan for biopsy of suspicious lung mass based on imaging (growth on serial
CT scan or nodule/mass with focal hypermetabolism on FDG-PET scan), OR
- Known metastatic cancer, with metastases to the lung based on imaging
- Age > 18 years old
- Eastern Clinical Oncology Group (ECOG) performance status 0, 1 or 2 (Appendix IV)
- No prior surgery, chemotherapy, or radiation for the current lung tumor
EXCLUSION CRITERIA
- Prior radiotherapy to thorax
- Iodine allergy
- Contraindication to receiving radiotherapy, unless undergoing surgery
- Pregnant
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting